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diagnosis. The newly applied chemotherapeutic agents in combination 
with radiotherapy shows improved response rate and survival. This 
study aimed to compare the effects of concurrent radiation and weekly 
cisplatin doublets with paclitaxel, or docetaxel, or gemcitabine.
Methods: Main eligibility criteria consisted of previously untreated 
stage IIIB NSCLC, age 18-75 years, PS ≤ 2, weight loss < 5%. After 
the informed consent, patients were randomized according to histology 
and institution. Since March 2005, eligible patients were randomized 
into three arms: paclitaxel 45mg/m2/week(TP), docetaxel 20mg/m2/
week(DP), gemcitabine 350mg/m2/week(GP) in addition to cisplatin 
20mg/m2/week. Three-dimensional conformal radiotherapy (3DCRT) 
was given once daily, 2-2.4Gy fraction to the GTV, weekly 5 fractions 
and the total prescription dose was over 60 Gy. Chemotherapy was 
initiated concurrently with the ﬁrst date of radiotherapy and repeated 
weekly for the following 6 weeks. Four weeks after the completion of 
CCRT, we proceeded to the three weekly consolidation chemotherapy: 
Paclitaxel 150mg/m2, docetaxel 75mg/m2, gemcitabine 1250mg/m2 
with cisplatin 60mg/m2. The primary end-point was response rate and 
the secondary end-points were survival and toxicity. Tumor response 
was measured on the basis of CT and/or PET-CT imaging using WHO 
criteria. Toxicities were evaluated by RTOG and NCI-CTC criteria.
Results: This trial is on-going at the present time. For this preliminary 
analysis, we included the ﬁfty-one patients (TP: 19, DP: 14, GP: 18) 
who completed the CCRT by October 2006. Similar overall response 
rates are observed; TP: 94.7%, GP: 92.9%, DP: 94.4%, respectively 
(p=1.0). There is no signiﬁcant difference in median survival; TP: not 
reached, GP: 13 months, DP: not reached (p=0.31). Radiation esopha-
gitis (≥grade 2) was noted in 5%(TP), 3%(DP), and 8%(GP, p=0.673) 
and radiation pneumonitis(≥grade 2) was observed in 2%(TP), 0%(DP), 
and 6%(GP, p=0.017). During the CCRT, both hematologic (p=0.31) 
and non-hematologic toxicities (p=0.27) were not different in three 
arms.
Conclusions: Among the 3 arms, no signiﬁcant difference in response 
rate and survival is observed. Tendency of different toxicity proﬁles are 
being observed.
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Background: The combination of chemotherapy and thoracic radiation 
is considered the standard treatment for locally advanced non-small 
cell lung cancer (NSCLC). However, the most favorable chemotherapy 
regime, timing of full-dose chemotherapy and the best way to combine 
chemotherapy with radiation to maximize systemic and radiosensitizing 
effects remains to be determined. The primary objective of this study 
was to evaluate the efﬁcacy and safety as well as tolerability of gem-
citabine with concurrent radiotherapy for locally advanced NSCLC.
Patients and Methods: Seventeen patients with histologically proven 
stage IIIA and IIIB NSCLC with no concurrent diseases and ECOG 
performance status 0-2 were included. Carboplatin was administered at 
an AUC of 2.5 and gemcitabine at 800mg/m2. Both drugs were given 
on day 1 and 8, every 21 days for two cycles, followed by conventional 
fractioned thoracic radiotherapy up to 60 Gy and concomitant weekly 
gemcitabine 200mg, followed by another 4 chemotherapy cycles post 
radiotherapy. 
Results: Ten patients (63%) had stage IIIB disease. Partial response 
was observed in 9 patients (57.1%) following induction chemotherapy. 
The most common hematological side effects were anemia (15.8%) 
neutropenia (15.8%) and thrombocytopenia (15.8%). Ten per cent 
experienced grade 3/4 emesis after the chemotherapy was given. After 
concurrent chemo-radiotherapy, global response was 66.7%, and 
grade 3/4 pneumonitis and anemia was observed in 28.6 and 15.8% 
respectively. Four patients (23%) underwent surgical resection. One 
treatment-related death from radiation pneumonitis occurred. Median 
progression-free survival was 18 ± 8.3 months. 
Conclusion: Induction chemotherapy with gemcitabine and carboplatin 
followed by concurrent chemoradiotherapy with gemcitabine followed 
by consolidation chemotherapy showed a response rate that is par-
ticularly noteworthy, considering the advanced stage and its favorable 
tolerability proﬁle.
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Background: Concomitant chemoradiation is the treatment of choice 
for locally advanced non small cell lung cancer (NSCLC). The EGF re-
ceptor is activated after radiation and may be implicated in tumour cell 
repopulation. Geﬁtinib (“Iressa”) enhances tumour radioresponsive-
ness in pre-clinical studies. These observations provide a rationale for 
combining geﬁtinib and chemoradiation. This study was undertaken to 
establish the maximum tolerated dose of the combination, and its effect 
on response and survival in NSCLC. 
Methods: Patients with a histologic diagnosis of NSCLC stage III 
disease (no pleural effusion or cervical lymphadenopathy), ECOG 
performance status 0/1, weight loss less than 10%, and no prior treat-
ment were eligible. Patients received radiotherapy 60Gy in 30 fractions 
over six weeks to the primary site and involved lymph nodes. Concur-
rent oral geﬁtinib 250mg per day and carboplatin AUC2 weekly were 
administered with radiotherapy on dose level 1 and weekly paclitaxel 
was added at 25, 35 and 45mg/m2 at dose levels 2, 3 and 4 (expanded 
cohort). The ﬁrst six patients continued geﬁtinib after chemoradiation 
however the protocol was amended to cease geﬁtinib at the end of 
chemoradiotherapy following reports of interstitial lung disease.
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Results: A total of 28 patients were enrolled on this study from four 
institutions between 15/7/02 and 11/7/05. Patient characteristics: me-
dian age 65 (range 50 - 75). Male 61%. Performance status 0/1:11/17. 
Histology: squamous/mixed 12, adenocarcinoma 6, large cell/undif-
ferentiated 10. Stage IIA 1, IIIA 16, IIIB 11. All patients received 60Gy. 
Chemotherapy dose was successfully escalated to level 4 (expanded 
cohort: 16 patients). No DLT’s were observed during the escalation 
phase. Response (28 patients evaluable): overall response rate 61% on 
PET scan, 46% on CT; complete response 43% (PET) 21% (CT). Of 16 
patients failing, ﬁrst site of progression was locoregional: 11, distant: 
4 and both: 1. At the close-out date 31/10/06 median survival had not 
been reached and survival at 24 months was 60% (95% CI: 39-82%).
Conclusions: Geﬁtinib 250mg per day can be safely given with full 
dose chemoradiation consisting of 60Gy plus carboplatin and paclitax-
el. Locoregional progression is the major cause of treatment failure.
Acknowledgment: Study supported by Astra Zeneca.
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Background: Combined modality therapy remains the best chance of 
cure in the setting of locally advanced NSCLC. The optimal combina-
tion of concurrent chemotherapy and radiation (CRT) continues to 
evolve. In this study we report our single institution experience with 
tri-modality therapy in patients with Stage III NSCLC.
Methods: 55 patients with Stage III NSCLC and ECOG 0-1 were 
prospectively studied between September 1995 and March 2004 at 
CancerCare Manitoba, Winnipeg, Canada. From 1995 through 1997, 
the standard regimen (PE) consisted of Cisplatin (25 mg/m2) & Eto-
poside (100 mg/m2) for 3 days every 3 weeks for 2 cycles combined 
with either radical intent (5000 cGy in 20 fractions) or palliative intent 
(3000-3500 cGy in 10 fractions) concurrent radiation. In 1998, the stan-
dard regimen was switched to TC using Carboplatin (AUC 3) & Pacli-
taxel (45mg/m2) once weekly for 4-6 weeks combined with 5000 cGy 
in 20 fractions. After a treatment related death in 1999, the Carboplatin 
dose was reduced (AUC 2) and radiation was revised to either 4500 
cGy in 25 fractions for Stage IIIa or 6000 cGy in 30 fractions for Stage 
IIIb disease. All patients were assessed for clinical response, toxicity, 
surgical resection, pathologic response, and survival.
Results: Median age was 62, Stage IIIa 59%, and Adenocarcinoma 
43%. Eighty-eight percent of patients received their prescribed dose of 
PE and 90% received at least four cycles of prescribed TC chemothera-
py. Radical radiation therapy was the intended therapy in 95% of cases 
however only 75% of patients received at least 5000 cGy of radiation. 










Cisplatin & Etoposide (PE) 26 0 (0%) 17 (59%) 8 (28%) 4 (14%)
Carboplatin & Paclitaxel (TC) 29 2 (8%) 8 (31%) 8 (31%) 8 (31%)
Grade 3 toxicity occurred in 2 patients on PE and 10 on TC. One 
patient receiving TC died of treatment related toxicity. Ten patients in 
each chemotherapy group went on to surgical resection with partial 
pathologic response seen in 50% PE and 80% TC. Median survival 
was 2.05 years for this population with no signiﬁcant survival differ-
ence between treatment groups (PE 2.25 vs. TC 1.98 years, p = 0.39). 
Dose of radiation (≥5000 cGy vs. <5000 cGy) did not signiﬁcantly 
impact survival. Patients who proceeded to surgical resection survived 
a median of 3.33 years compared to 1.62 years for un-resected patients 
(p = 0.0006).
Conclusions: In our experience, both combinations of chemotherapy 
combined with radiation were equally effective in terms of overall sur-
vival in Stage III NSCLC. TC based CRT appears to have better clini-
cal and pathologic response compared to PE at the expense of a slight 
increase in treatment related toxicity. The few patients who proceeded 
to surgery post CRT had signiﬁcantly improved survival.
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Background: Purpose of this study was to evaluate feasibility of 
thoracic radiotherapy (TRT) with concurrent daily low-dose carboplatin 
for inoperable stage III NSCLC in elderly or frail patients in the Central 
European population. 
Methods: Modiﬁed Japanese treatment protocol originally published 
by Atagi et al (Jpn J Clin Oncol, 30, 2, 59-64) was used. TRT 60 Gy (2 
Gy fractions, 5 days a week) was administered over a 6-week period. 
Carboplatin 25 mg/m2 as a 30 min infusion was given one hour before 
TRT, daily, over four weeks, starting on day one. The eligibility criteria 
for patients included: age 65 years or over with ECOG PS 0 - 2 or 
younger with ECOG PS 2, histologically and/or cytologically con-
ﬁrmed NSCLC, inoperable stage III disease, satisfactory blood count 
and standard biochemical parameters. There was no age-limit. 
Results: Twenty patients were treated. Patients´ characteristics: elderly/
non-elderly: 18/2, age - median: 73.5 years (range: 55 - 80), male/fe-
male: 18/2, ECOG PS 0/1/2: 0/10/10, squamous cell carcinoma/adeno-
carcinoma: 18/2. All patients were assessable for treatment response 
and toxicity. In fourteen was it possible to administer the entire proto-
col therapy without any disruption. The response by the end of treat-
ment was: complete response: 0, partial response: 12 (60%; 95%CI: 39 
- 78%), stable disease: 7 (35%; 95%CI: 18 - 57%), progressive disease: 
1 (5%; 95%CI: 1 - 24%). Survival time - median: 19 months (range: 3 
- 36+; 95%CI: 10 - 26), 2-year survival rate - 35% (95%CI: 18 - 57%). 
Main toxicities were as follows: NCI CTC grade 3/4 neutropenia in 
25/5%, thrombocytopenia in 15/5%, febrile neutropenia in 5/0%, respi-
ratory infection in 10/0%, and esophagitis in 5/0%. Transfusions and/or 
erythropoietin were given due to grade 2 anemia in 40% of patients. All 
toxicities were manageable and there was no treatment related death.
Conclusion: TRT with daily low-dose carboplatin was feasible in our 
group of patients. Response rates and survival are comparable with 
those achieved in younger good prognosis patients by more sophisti-
cated combinations of TRT and chemotherapy. 
